BiochemistrybioRxiv
Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding
M. J. McCarthy, C. V. Pagba, P. Prakash…·A. A. Gorfe
This study identifies a pyrazolopyrimidine-based allosteric KRAS inhibitor with sub-micromolar affinity that disrupts effector binding and inhibits cancer cell growth.
DOI 10.1021/acsomega.8b03308